Evidence map›Paper›PMID 38293162›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosis.

Olivia C Leavy, Anne F Goemans, Amy D Stockwell, Richard J Allen, Beatriz Guillen-Guio, Tamara Hernandez-Beeftink, Ayodeji Adegunsoye, Helen L Booth, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, Paul Cullinan and 34 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 20 institutions in 5 countries.

Olivia C LeavyDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-1503-5535
Anne F GoemansDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0009-0004-4014-4735
Amy D StockwellGenentech, California, USA.
Richard J AllenDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-8450-3056
Beatriz Guillen-GuioDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-3703-1738
Tamara Hernandez-BeeftinkDepartment of Population Health Sciences, University of Leicester, Leicester, UK.
Ayodeji AdegunsoyeUniversity of Chicago, Chicago, USA.ORCID 0000-0002-7015-9610
Helen L BoothUniversity College London Hospitals, London, UK.
CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
Paul CullinanImperial College, London, UK.
William A FahyGlaxoSmithKline, London, UK.
Tasha E FingerlinNational Jewish Health, Colorado, USA.
Harvinder S VirkNIHR Leicester Biomedical Research Centre, Leicester, UK.
Ian P HallUniversity of Nottingham, Nottingham, UK.
Simon P HartUniversity of Hull, Hull, UK.
Mike R HillUniversity of Oxford, Oxford, UK.
Nik HiraniUniversity of Edinburgh, Edinburgh, UK.
Richard B HubbardUniversity of Nottingham, Nottingham, UK.
Naftali KaminskiYale School of Medicine, Connecticut, USA.ORCID 0000-0001-5917-4601
Shwu-Fan MaUniversity of Virginia, Virginia, USA.ORCID 0000-0002-3058-9480
Robin J McAnultyUniversity College London, London, UK.ORCID 0000-0003-1936-4245
X Rebecca ShengGenentech, California, USA.
Ann B MillarUniversity of Bristol, Bristol, UK.
Maria Molina-MolinaServei de Pneumologia, Laboratori de Pneumologia Experimental, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Vidya NavaratnamDepartment of Respiratory Medicine, Sir Charles Gardiner Hospital, Perth, Australia.ORCID 0000-0002-2914-8012
Margaret NeighborsGenentech, California, USA.
Helen ParfreyRoyal Papworth Hospital NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-4515-5634
Gauri SainiUniversity of Nottingham, Nottingham, UK.
Ian SayersCentre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0001-5601-5410
Mary E StrekUniversity of Chicago, Chicago, USA.ORCID 0000-0002-7671-1023
Martin D TobinDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-3596-7874
Moira Kb WhyteUniversity of Edinburgh, Edinburgh, UK.
Yingze ZhangUniversity of Pittsburgh, Pittsburgh, USA.
Toby M MaherNIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0001-7192-9149
Philip L MolyneauxNational Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.ORCID 0000-0003-1301-8800
Justin M OldhamUniversity of Michigan, Michigan, USA.ORCID 0000-0003-4957-8869
Brian L YaspanGenentech, California, USA.ORCID 0000-0002-3787-2510
Carlos FloresResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.ORCID 0000-0001-5352-069X
Fernando MartinezWeill Cornell Medicine, New York, USA.
Carl J ReynoldsImperial College, London, UK.ORCID 0000-0002-7415-258X
David A SchwartzUniversity of Colorado Medicine, Colorado, USA.
Imre NothUniversity of Virginia, Virginia, USA.ORCID 0000-0001-9846-5030
R Gisli JenkinsNIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-7929-2119
Louise V WainDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0003-4951-1867
University of Leicester · GBUniversity of Nottingham · GBCornell University · USNational Institute for Health Research · GBUniversity of Southern California · USGlaxoSmithKline (Netherlands) · NLGlaxoSmithKline (United Kingdom) · GBImperial College London · GBImperial Valley College · USInstituto de Salud Carlos III · ESLung Institute · USNational Jewish Health · USPapworth Hospital NHS Foundation Trust · GBRoyal London Hospital · GBThe University of Western Australia · AUUniversity College London · GBUniversity of Bristol · GBUniversity of Chicago · USUniversity of Hull · GBUniversity of Michigan · US

Funding

Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Epithelial Protective Effects of Thyroid Hormone Signaling in FibrosisR01HL141852 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$3.4M
Normal Aging Lung Cell Atlas (NALCA)U01HL145567 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$2.8M
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
Integrating single-cell based transcriptomic signatures for identifying therapeutic targets of COPDR21HL161723 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2022 to 2023
$251k
Medical Research Council MC_PC_19004NHLBI NIH HHS K23 HL138190NHLBI NIH HHS K23 HL146942NHLBI NIH HHS R01 HL127349NHLBI NIH HHS R01 HL141852NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R21 HL161723NHLBI NIH HHS U01 HL145567NHLBI NIH HHS UG3 HL145266Wellcome Trust
6 · The paper itself

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition that is more prevalent in males than females. The reasons for this are not fully understood, with differing environmental exposures due to historically sex-biased occupations, or diagnostic bias, being possible explanations. To date, over 20 independent genetic variants have been identified to be associated with IPF susceptibility, but these have been discovered when combining males and females. Our aim was to test for the presence of sex-specific associations with IPF susceptibility and assess whether there is a need to consider sex-specific effects when evaluating genetic risk in clinical prediction models for IPF. Methods: We performed genome-wide single nucleotide polymorphism (SNP)-by-sex interaction studies of IPF risk in six independent IPF case-control studies and combined them using inverse-variance weighted fixed effect meta-analysis. In total, 4,561 cases (1,280 females and 2,281 males) and 23,500 controls (8,360 females and 14,528 males) of European genetic ancestry were analysed. We used polygenic risk scores (PRS) to assess differences in genetic risk prediction between males and females. Findings: Three independent genetic association signals were identified. All showed a consistent direction of effect across all individual IPF studies and an opposite direction of effect in IPF susceptibility between females and males. None had been previously identified in IPF susceptibility genome-wide association studies (GWAS). The predictive accuracy of the PRSs were similar between males and females, regardless of whether using combined or sex-specific GWAS results. Interpretation: We prioritised three genetic variants whose effect on IPF risk may be modified by sex, however these require further study. We found no evidence that the predictive accuracy of common SNP-based PRSs varies significantly between males and females.

Identifiers

PMID38293162
PMCPMC10827242
OpenAlexW4390838459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.